key: cord-0769858-gunx38ku
authors: Levy, Jerrold H.; Tanaka, Kenichi A.
title: Can We Use Viscoelastic Testing to Evaluate Microvascular Dysfunction in Acute Myocardial Infarction?
date: 2021-10-25
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2021.07.006
sha: b68519430e095bd200fb53f57808d2655fc7df88
doc_id: 769858
cord_uid: gunx38ku

[Figure: see text]

T he assessment and application of hypercoagulability characteristics in routine clinical practice continue to be important but poorly defined issues. It is a logical consideration that in the setting of acute vascular injury, a prothrombotic milieu resulting in occlusive clot generation will accelerate the progression and worsening of organ injury, especially for highly vascular organs. The current pandemic and increasing number of publications reporting hypercoagulability in the setting of microcirculatory and endothelial injury associated with SARS-CoV-2 viral infections has increased this recognition (1) . In addition, the widespread use of laboratory testing and critical biomarkers to determine adverse thrombotic outcomes in COVID-19 has increased awareness of the role of hypercoagulability for clinicians, as prognostic tests that include D-dimer and fibrinogen levels, but also with increasing reports of viscoelastic testing (1).

Viscoelastic testing with the currently available point-of-care monitoring systems has also been increasingly reported as a diagnostic tool beyond bleeding management in surgery and trauma for its 

COVID-19 and its implications for thrombosis and anticoagulation

Association between thrombogenicity indices and coronary microvascular dysfunction in patients with acute myocardial infarction

The contribution of the individual blood elements to the variability of thromboelastographic measures

Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention

Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding